These data suggested that invasive ovarian cancer at early stages (FIGO I and II) are associated with p53 alterations, whereas the progression of ovarian cancer to distant metastases (FIGO III and IV) is associated with tumours having nuclear WT1 expression. Here, WT1 is linked to neoplasm.